Skip to main content

Megan A. Baumgart, M.D.

Contact Information

Phone Numbers

Appointment: (585) 275-5823

Administrative: (585) 275-9319

Fax: (585) 273-5761

URMFGA member of the University of Rochester Medical Faculty Group

groupAn Accountable Health Partner

assignmentAccepting New Patients

Faculty Appointments

Patient Care Settings

Cancer, Hospital Medicine


I chose the field of oncology because I want to help patients through one of the most difficult experiences a person can have.

Cancer treatment requires a team approach involving the patient, medical oncologist, nurses and support staff, as well as other medical teams such as radiation oncology and surgery who are often part of a patient's care. I work with patients to help them understand the overall treatment plan – especially the role of chemotherapy in the treatment of their disease – and support them throughout the course of treatment.

I am optimistic about the future of cancer treatment and want to work towards finding new and better treatment strategies for lung and head and neck cancers through the development of our clinical trials program. We currently have several clinical trials evaluating the role of immunotherapy for the treatment of metastatic head and neck cancers open for enrollment, as well as other clinical trials focused on answering important questions regarding the management of these diseases.

Conditions I Treat

- Small cell lung cancer
- Non-small cell lung cancer
- Head and neck cancers
- Thyroid cancer



MD | Albany Medical College

Post-doctoral Training & Residency

07/01/2011 - 06/30/2014
Fellowship in Medical Oncology at Yale New Haven Hospital

07/01/2008 - 06/30/2010
Residency in Internal Medicine at Rhode Island Hospital GME

06/20/2007 - 06/30/2008
Internship in Internal Medicine at Rhode Island Hospital GME

VIEW ALL expand_more


2019 - Present
Early Career Women Faculty Leadership Development Seminar
Sponsor: AAMC Application Selection Committee

Annual Award for Outstanding Oncology Research
Sponsor: Yale University Medical Oncology and Hematology Fellowship
Location: New Haven, CT

Albany Medical College- Distinction in Biomedical Ethics
Location: Albany, NY

VIEW ALL expand_more

Clinical Trials

A pilot study of pembrolizumab and single agent chemotherapy as first line treatment for patients with locally advanced or metastatic non-small cell lung cancer with Eastern Cooperative Oncology Group (ECOG) performance status of 2

Lead Researcher: Megan A Baumgart

The purpose of this study is to understand if treatment with one chemotherapy medication combined with immune therapy (pembrolizumab) is tolerable and effective for patients with lung cancer and performance status of 2 (PS2), which means you have limitations in carrying out certain activities or spend up to half of your day resting.

View Study Details

A Phase II Study of AMG 510 in Participants With Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LUNG-MAP SUB-STUDY)

Lead Researcher: Megan A Baumgart

This phase II Lung-MAP treatment trial studies the effect of AMG 510 in treating non-squamous non-small cell lung cancer that is stage IV or has come back (recurrent) and has a specific mutation in the KRAS gene, known as KRAS G12C. Mutations in this gene may cause the cancer to grow. AMG 510, a targeted treatment against the KRAS G12C mutation, may help stop the growth of tumor cells.

View Study Details

Nivolumab Versus Observation in Treating Patients With Locally Advanced, Intermediate Risk HPV-Positive Oropharyngeal Cancer (EA3161)

Lead Researcher: Megan A Baumgart

This phase III trials studies whether maintenance immunotherapy (nivolumab) following definitive treatment with radiation and chemotherapy (cisplatin) result in significant improvement in overall survival (time being alive) and progression-free survival (time being alive without cancer) for patients with intermediate risk human papillomavirus (HPV) positive oropharynx cancer (throat cancer) that has spread to nearby tissue or lymph nodes. Drugs used in chemotherapy such as cisplatin work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy rays to kill tumor cells and shrink tumors. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. It is not yet known whether chemotherapy and radiation therapy followed by maintenance nivolumab therapy works better than chemotherapy and radiation therapy alone in treating patients with HPV positive oropharyngeal cancer.

View Study Details

LUNGMAP: A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study)

Lead Researcher: Megan A Baumgart

This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of care therapy with the ultimate goal of being able to approve new targeted therapies in this setting. In addition, the protocol includes non-match sub-studies which will include all screened patients not eligible for any of the biomarker-driven sub-studies.

View Study Details


Journal Articles

Baumgart, M.; Bazhenova, L.; Haggstrom, D.; Baranda, J.; Belani, C. "PUB031 PRIMAL: A Phase 1b Study of PEGPH20 plus Docetaxel in Patients with Previously Treated Hyaluronan (HA)-High Advanced NSCLC". Journal of Thoracic Oncology. 2017; 12(1): S1465.

Abu-Khalaf MM, Baumgart MA, Gettinger SN, Doddamane I, Tuck DP, Hou S, Chen N, Sullivan C, Lezon-Geyda K, Zelterman D, Hatzis C, Deshpande H, Digiovanna MP, Azodi M, Schwartz PE, Harris LN. "Phase 1b study of the mammalian target of rapamycin inhibitor sirolimus in combination with nanoparticle albumin-bound paclitaxel in patients with advanced solid tumors." Cancer.. 2015 Jun 1; 121(11):1817-26. Epub 2015 Feb 03.

Baumgart, M. "New molecular targets on the horizon in non-small cell lung cancer" . American Journal of Hematology and Oncology. 2015; 11(6): 10-13.